In early trading on Thursday, Eli Lilly (LLY) shares rose 1.9% after the company reported better-than-expected third-quarter results, driven by surging sales of Zepbound (tirzepatide) and Mounjaro. The pharmaceutical giant also raised its revenue and earnings per share guidance for 2025.